Amiselimod Two-Phase Dosing for Ulcerative Colitis

The patent applies parameter changes by implementing a two-phase dosing regimen where the dose amount varies over time. The loading phase uses higher doses (0.3-1.0 mg/day) to rapidly achieve therapeutic effect, then transitions to a maintenance phase with lower doses (0.1-0.3 mg/day) to sustain efficacy while minimizing side effects. This dynamic parameter adjustment resolves the contradiction between achieving reliable treatment efficacy and avoiding safety limitations.

The patent segments the treatment into two distinct phases: a loading phase (first administration period) and a maintenance phase (second administration period). This segmentation allows the dosing regimen to achieve therapeutic steady-state concentration through the initial loading phase while simplifying long-term management through the reduced-dose maintenance phase. The segmentation resolves the contradiction by dividing the complex dosing requirement into manageable temporal stages.

The patent implements periodic action through its two-phase dosing structure. The loading phase provides periodic high-dose administrations to maximize therapeutic effect and rapidly reduce inflammation. The transition to the maintenance phase with lower periodic doses sustains therapeutic effect while reducing the frequency and intensity of negative chronotropic effects. This periodic variation in dosing resolves the contradiction between maximizing therapeutic effect and minimizing harmful cardiac side effects.